How effective is the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) in different patient populations, and when should it be used in clinical practice?

Abstract

The efficacy and safety of the fixed-ratio combination of insulin degludec (degludec) and liraglutide (IDegLira) were confirmed in the DUAL clinical trial program, in which IDegLira demonstrated superior or noninferior glycemic control over comparators in addition to its low risks of hypoglycemia and weight gain. This article identifies the patient types for whom IDegLira is most appropriate by reviewing the DUAL results and subsequent post hoc analyses and presenting real-world cases inwhich IDegLira has been used effectively in U.S. clinical practice. In the clinic, IDegLira has been used effectively when patientswanted to avoid more complex injectable regimens, particularly those with renal insufficiency for whom treatment options are limited.